Three common CFTR mutations should be included in a neonatal screening programme for cystic fibrosis in Sweden

Clinical Genetics

Volumn 56, Issue 4, 1999, Pages 318-322

  Schaedel, Charlotta ^a   Hjelte, L ^b   De Monestrol, I ^b   Johannesson, M ^c   Kollberg, H ^c   Kornfalt R ^a   Holmberg, L ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CFTR gene test; Cystic fibrosis; Neonatal screening; Nutrition; Trypsinogen

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADULT; ALLELE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC ERROR; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MUTATION RATE; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL; SWEDEN;

EID: 0032746468     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.1999.560410.x     Document Type: Article

References (22)

1. Farrell PM, Kosorok MR, Laxova A, Shen G, Koscik RE, Bruns T, Splaingard M, Mischler EH. Nutritional benefits of neonatal screening for cystic fibrosis. New Engl J Med 1997: 337: 963-969.
2. Dankert-Roelse JE, te Meerman GJ. Long-term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis center. Thorax 1995: 50: 712-718.
3. Waters D, Wilcken B, Irwig L, Van Asperen P, Mellis C, Simpson J, Brown J, Gaskin K. Clinical outcomes of newborn screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999: 80: F1-F7.
4. Crossley JR, Elliot RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979: 1: 472-474.
5. Farrell PM, Mischler EH. Newborn screening for cystic fibrosis: the cystic fibrosis neonatal screening group. Adv Pediatr 1992: 39: 35-70.
6. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr 1995: 127: 965-970.
7. Gregg RG, Simantel A, Farrell PM, Koscik R, Kosorok MR, Laxova A, Laessig R, Hoffman G et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics 1997: 99: 819-824.
8. Ranieri E, Lewis BD, Gerace RL, Ryall RG, Morris CP, Nelson PV, Carey WF, Robertson EF. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. Br Med J 1994: 308: 1469-1472.
9. World Medical Association Declaration of Helsinki. Adopted by the 18th World Medical Assembly (Helsinki, 1964), as revised by the 48th World Medical Assembly, 1996.
10. Blin N, Stafford D. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976: 3: 2303-2308.
11. Zielenski J, Rozmahel R, Bozon D, Kerem B-S, Grzelczak Z, Riordan JR, Rommens J, Tsui L-C. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics 1991: 10: 214-228.
12. Schaedel C, Schwartz M, Kornfält R, Holmberg L. Cystic fibrosis caused by homozygosity for the CFTR gene mutation 175insT. Acta Paediatr 1995: 84: 1199-1200.
13. Waters DL, Dorney FA, Gaskin KJ, Gruca MA, O'Halloran M, Wilcken B. Pancreatic function in infants identified as having cystic fibrosis in a neonatal screening program. New Engl J Med 1990: 322: 303-308.
14. Bronstein MN, Sokol RJ, Abman SH, Chatfield BA, Hammond KB, Hambidge KM, Stall CD, Accurso FJ. Pancreatic insufficiency, growth and nutrition in infants identified by newborn screening as having cystic fibrosis. J Pediatr 1992: 120: 533-540.
15. Giglio L, Candusso M, D'Orazio C, Mastella G, Faraguna D. Failure to thrive: the earliest feature of cystic fibrosis in infants diagnosed by neonatal screening. Acta Paediatr 1997: 86: 1162-1165.
16. Larsen J, Cambell S, Faragher EB, Götz M, Eichler I, Waldherr S, Dobianer K, Spona J. Cystic fibrosis screening in neonates-measurement of immunoreactive trypsin and direct genotype analysis for ΔF508 mutation. Eur J Pediatr 1994: 153: 569-573.
17. Balvanes ME, Bonacquisto L, Francis I, Glazner J, Forrest S. The impact of newborn screening on cystic fibrosis testing in Victoria, Australia. J Med Genet 1995: 32: 537-542.
18. Schwartz M, Johansen HK, Koch C, Brandt NJ. Frequency of the ΔF508 mutation on cystic fibrosis chromosomes in Denmark. Hum Genet 1990: 85: 427-428.
19. Kere J, Estivill X, Chillon M, Morral N, Nunes V, Norio R, Savilathi E, de la Chapelle A. Cystic fibrosis in a low-incidence population: two major mutations in Finland. Hum Genet 1994: 93: 162-166.
20. Schwartz M, Anvret M, Claustres M, Eiken HG, Eiklid K, Schaedel C, Stolpe L, Tranebjaerg L. 394de1TT: a Nordic cystic fibrosis mutation. Hum Genet 1994: 93: 157-161.
21. Kerem B-S, Zielenski J, Markiewicz D, Bozon D, Gazit E, Yahav J, Kennedy D, Riordan JR, Collins F, Rommens J, Tsui L-C. Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci 1990: 87: 8447-51.
22. Dahl N, Grandell U, Martinsson T, Allen M, Johansson L, Stolpe L, Gyllensten U, Hjelte L, Kollberg H, Strandvik B, Wahlström J, Anvret M. Frequency of four cystic fibrosis mutations in a Swedish population. Acta Paediatr 1993: 82: 609.